Index

Note: Page numbers of article titles are in **boldface** type.

A

Acarbose
  in fecal flora modulation
    in OHE management, 81–82
Activated charcoal
  ammonia reduction by
    in OHE management, 81
Adipopenia
  defined, 97
Adult fat malnutrition
  defined, 97
Aging
  cirrhosis effects of, 113
Amino acid imbalance
  false neurotransmitters and
    in HE pathogenesis, 11
γ-Aminobutyric acid (GABA)
  ammonia and brain extracellular concentrations of
    in HE pathogenesis, 19
γ-Aminobutyric acid (GABA)–mediated inhibitory neurotransmission
  in HE pathogenesis, 11–16
γ-Aminobutyric acid (GABA) receptor
  ammonia effects on, 17
γ-Aminobutyric acid (GABA) receptor complex
  synergistic interaction between ammonia and agonist ligands of, 17–19
Ammonia
  neurosteroids and
    in HE pathogenesis, 19
  reduction of
    nonabsorbable disaccharides in
      in OHE management, 79–81
Ammonia hypothesis
  in HE pathogenesis, 9–10, 16–19
    ammonia and brain extracellular concentration of GABA, 19
    ammonia and neurosteroids, 19
    ammonia effects on GABA<sub>α</sub> receptor, 17
    significance of ammonia concentrations in, 17
    synergistic interaction between ammonia and agonist ligands of GABA<sub>α</sub> receptor complex, 17–19
    variants of, 10

doi:10.1016/S1089-3261(12)00011-6
liver.theclinics.com
1089-3261/12/$ – see front matter © 2012 Elsevier Inc. All rights reserved.
Ammonia scavengers
  ammonia reduction by
    in OHE management, 81
Antibiotics
  in fecal flora modulation
    in OHE management, 81–82

B
Benzodiazepine(s)
  natural
    accumulation of
      in HE pathogenesis, 13–15
BIS. See Bispectral index (BIS)
Bispectral index (BIS)
  in semiquantification of OHE, 37–38
Brain
  in HE mediation, 8–9
    imaging of
      in HE assessment, 57–72. See also specific modalities
        MRI, 58–63
        MRS, 63–65
        nuclear medicine, 65–67
        PET, 65–67
        SPECT, 65–67

C
Cachexia
  defined, 97
    hepatic
      defined, 97
Cerebral energy metabolism
  decreased
    in HE pathogenesis, 10
CFF. See Critical Flicker Frequency (CFF)
Charcoal
  activated
    ammonia reduction by
      in OHE management, 81
CHESS. See Clinical Hepatic Encephalopathy Staging Scale (CHESS)
Children
  malnutrition in
    defined, 96
Choice tests
  in MHE assessment, 48
Cirrhosis. See also Liver disease
  aging patients with, 113
    assessment of
      testing in, 44
    malnutrition in, 95–131. See also Malnutrition, in cirrhosis
    posttransplant patients with, 113–116
sarcopenia in
pathogenesis and mechanisms of, 105, 110–113. See also Sarcopenia, in cirrhosis,
pathogenesis and mechanisms of
protein metabolism, 110–111

spectrum of neurocognitive impairment in, 2–4

Clinical Hepatic Encephalopathy Staging Scale (CHESS)
in semiquantification of OHE, 31–32

Clinical scales
in semiquantification of OHE, 27–42
CHESS, 31–32
GCS, 32
HESA, 29–31
West Haven Criteria (Conn Score), 28–29

Cognitive Drug Research Computerized Assessment System
in MHE assessment, 50

Computerized psychometric tests
in MHE assessment, 48–51

Conn Score
in semiquantification of OHE, 28–29

Continuous reaction times (CRTs)
in semiquantification of OHE, 35

Covert hepatic encephalopathy (HE). See also Minimal hepatic encephalopathy (MHE)
described, 91
diagnosis of, 91–92
management of, 91–93

Critical Flicker Frequency (CFF)
in MHE assessment, 52
in semiquantification of OHE, 34–35

D

Depression
HRQoL and, 166

Diffusion-weighted imaging (DWI)
in HE assessment, 60–62

Disaccharides
nonabsorbable
ammonia reduction by
in OHE management, 79–81

E

EEG. See Electroencephalography (EEG)

Electroencephalography (EEG)
in MHE assessment, 51
in semiquantification of OHE, 37

Encephalopathy(ies)
hepatic. See Hepatic encephalopathy (HE)
portal-systemic. See Hepatic encephalopathy (HE)

Energy malnutrition
defined, 96–97
Evoked potentials
   for semiquantification of OHE, 37
Exercise
   for malnutrition management in cirrhosis, 117, 121
Extracorporeal liver devices
   in OHE management, 84

F
Fast FLAIR imaging
   in HE assessment, 60
Fecal flora
   modulation of
      in OHE management
         oral antibiotics, prebiotics, probiotics, and acarbose in, 81–82
Functional MRI
   in HE assessment, 63

G
GABA. See γ-Aminobutyric acid (GABA)
GCS. See Glasgow Coma Scale (GCS)
Glasgow Coma Scale (GCS)
   in semiquantification of OHE, 32
Glutamate-mediated excitatory neurotransmission
   in HE pathogenesis, 16

H
HE. See Hepatic encephalopathy (HE)
Health-related quality of life (HRQoL)
   depression and, 166
   described, 159
HE and, 159–170
   in cirrhosis, 163
      described, 159–167
      studies of, 162–164
         treatment effects of, 167
      measurement of, 160–161
      sleep disturbances and, 165–166
Hepatic cachexia
   defined, 97
Hepatic encephalopathy (HE)
   after liver transplantation
      reversibility of, 147–158
   after TIPS, 133–146. See also Transjugular intrahepatic portosystemic shunt (TIPS), HE after
   assessment of
brain imaging in, 57–72. See also Brain, imaging of, in HE assessment
burden of, 73–74
chronic recurrent
  treatment of, 139–142
covet
  management of, 91–93. See also Minimal hepatic encephalopathy (MHE)
defined, 1
described, 7, 27, 57, 73, 133–134
diagnosis of, 57–58, 74
disease process in, 57
episodic
  treatment of, 139
HRQoL and, 159–170. See also Health-related quality of life (HRQoL), HE and
minimal. See Minimal hepatic encephalopathy (MHE)
multiaxial classification of, 2
natural history of, 147–149
new perspectives in, 1–5
overt. See Overt hepatic encephalopathy (OHE)
pathogenesis of
  theories of, 7–26, 147–148
    altered neurotransmission, 11
    ammonia hypothesis, 9–10, 16–19
      variants of, 10
decreased cerebral energy metabolism, 10
false neurotransmitters and amino acid imbalance, 11
GABA-A–mediated inhibitory neurotransmission, 11–16
  accumulation of natural benzodiazepines, 13–15
evidence supporting, 11–13
  increased synaptic availability of GABA, 13
  mechanisms of, 13–16
  glutamate-mediated excitatory neurotransmission, 16
  imbalance between inhibitory and excitatory neurotransmission, 16
  synergistic neurotoxins, 10
pathophysiology of, 147–149
  mechanisms in, 27–28
prevalence of, 73
reversibility of
  concept of, 149
  liver transplantation in, 151–154
  medical treatment in, 149–151
signs and symptoms of, 165–166
treatment of, 147–149
types of, 1
HESA
  in semiquantification of OHE, 29–31
HRQoL. See Health-related quality of life (HRQoL)
I
ICT. See Inhibitory Control Test (ICT)
IGF1
in sarcopenia in cirrhosis, 113
ImPACT Assessment System
in MHE assessment, 50–51
Inhibitory Control Test (ICT)
in MHE assessment, 48–50
in semiquantification of OHE, 35–36

L
Liver disease. See also Cirrhosis
malnutrition in
definitions associated with, 96–97
severity of
sarcopenia effects of, 101
Liver transplantation
HE after
reversibility of, 147–158

M
Magnetic resonance imaging (MRI)
in HE assessment, 58–63
tfMRI, 63
MTI, 62–63
T1-weighted MRI, 58–60
T2-weighted MRI: DWI, 60–62
T2-weighted MRI: fast FLAIR imaging, 60
volumetric MRI, 62
for semiquantification of OHE, 36–37
Magnetic resonance spectroscopy (MRS)
in HE assessment, 63–65
proton
for semiquantification of OHE, 37
Magnetization transfer imaging (MTI)
in HE assessment, 62–63
Malnutrition
adult fat
defined, 97
in children
defined, 96
in cirrhosis, 95–131
aging effects on, 113
assessment of
methods in, 97–100
clinical complications associated with, 104–105, 108–109
clinical implications of, 101–105
definitions associated with, 96–97
described, 95–96
in posttransplant patients, 113–116
prevalence of, 98–101
quality of life effects of, 104, 106–107
survival rates, 101–104
treatment of, 116–121
  exercise in, 117, 121
  nutritional supplementation in, 116–117
energy
defined, 96–97
in liver disease
definitions associated with, 96–97
Mental status
  normal
    assessment of
      testing in, 44
MHE. See Minimal hepatic encephalopathy (MHE)
Minimal hepatic encephalopathy (MHE)
  assessment of, 43–55
    CFF in, 52
    Choice tests in, 48
    Cognitive Drug Research Computerized Assessment System in, 50
    computerized psychometric tests in, 48–51
    electrophysiologic, 51
    ICT in, 48–50
    ImPACT Assessment System in, 50–51
    paper and pencil psychometric tests in, 44–48
    PHES in, 45
    RBANS in, 45–48
described, 1–2
diagnosis of, 43–44, 57–58
management of, 91–93
MRS. See Magnetic resonance spectroscopy (MRS)
MTI. See Magnetization transfer imaging (MTI)

N
Neuropyschologistic tests
  in semiquantification of OHE, 36–38
    BIS, 37–38
    EEG and evoked potentials, 37
    MRI, 36–37
    proton MRS, 37
Neuropsychological tests
  in semiquantification of OHE
    CFF, 34–35
    continuous reaction times, 35
    ICT, 35–36
    PHES, 33–34
    PSE syndrome test, 33–34
    PSEI, 32–33
Neuropsychological (continued)
   RBANS, 34
   scan test, 36
Neurosteroids
   ammonia and
   in HE pathogenesis, 19
Neurotoxins
   synergistic
   in HE pathogenesis, 10
Neurotransmission
   altered
   in HE pathogenesis, 11
   excitatory
      glutamate-mediated
      in HE pathogenesis, 16
      imbalance between inhibitory and
      in HE pathogenesis, 16
   GABA_A-mediated inhibitory
   in HE pathogenesis, 11–16
   inhibitory
      imbalance between excitatory and
      in HE pathogenesis, 16
   modulation of
      in OHE management, 83
Neurotransmitter(s)
   false
   in HE pathogenesis
      amino acid imbalance and, 11
Nuclear medicine
   in HE assessment, 65–67
Nutritional deficiencies
   correction of
      in OHE management, 84
Nutritional supplementation
   in malnutrition management in cirrhosis, 116–117

O

OHE. See Overt hepatic encephalopathy (OHE)
Overt hepatic encephalopathy (OHE)
   described, 73–74
   diagnosis of, 74
   management of, 73–89
      ammonia reduction in
         by ammonia scavengers and activated charcoal, 81
         by nonabsorbable disaccharides, 79–81
      clinical guidelines for, 74–78
      extracorporeal liver devices in, 84
      fecal flora modulation in
         oral antibiotics, prebiotics, probiotics, and acarbose in, 81–82
      neurotransmission modulation in, 83
nutritional deficiencies correction in, 84
precipitating factors management in, 79
protein restriction in, 83–84
randomized controlled trials in, 76–78
rifaximin in, 82–83
shunting in, 84
prevalence of, 73
scoring systems for, 28–38. See also Neuropsychological tests; specific systems, e.g.,
Clinical scales
clinical scales, 28–32
neurophysiologic tests, 36–38
neuropsychological tests, 32–36
semiquantification of
clinical scales in, 27–42. See also Clinical scales, in semiquantification of OHE

P
Paper and pencil psychometric tests
in MHE assessment, 44–48
PET. See Positron emission tomography (PET)
PHES. See Psychometric Hepatic Encephalopathy Score (PHES)
Portal-systemic encephalopathy (PSE). See Hepatic encephalopathy (HE)
Portosystemic Encephalopathy Index (PSEI)
in semiquantification of OHE, 32–33
Portosystemic Encephalopathy (PSE) Syndrome Test
in semiquantification of OHE, 33–34
Portosystemic shunting
cirrhosis with
protein metabolism in, 110–111
Positron emission tomography (PET)
in HE assessment, 65–67
Posttransplant patients
cirrhosis in, 113–116
Prebiotics
in fecal flora modulation
in OHE management, 81–82
Precachexia
defined, 97
Probiotics
in fecal flora modulation
in OHE management, 81–82
Protein(s)
restriction of
in OHE management, 83–84
Protein metabolism
in cirrhosis with portosystemic shunting, 110–111
Proton magnetic resonance spectroscopy
in semiquantification of OHE, 37
PSE. See Portal-systemic encephalopathy (PSE)
PSE syndrome test. See Portosystemic Encephalopathy Syndrome Test
PSEI. See Portosystemic Encephalopathy Index (PSEI)
Psychometric Hepatic Encephalopathy Score (PHES)
  in MHE assessment, 45
  in semiquantification of OHE, 33–34

Q
Quality of life
  health-related
    HE and, 159–170. See also Health-related quality of life (HRQoL), HE and malnutrition in cirrhosis effects on, 104, 106–107

R
RBANS. See Repeatable Battery for the Assessment of Neuropsychological Status (RBANS)
Repeatable Battery for the Assessment of Neuropsychological Status (RBANS)
  in MHE assessment, 45–48
  in semiquantification of OHE, 34
Rifaximin
  in OHE management, 82–83

S
Sarcopenia
  in cirrhosis
    in aging patients, 113
    pathogenesis and mechanisms of, 105, 110–113
    IGF1 in, 113
    molecular regulation of skeletal muscle protein metabolism and satellite cell function in, 112–113
    protein metabolism in, 110–111
    satellite cells and skeletal muscle mass in, 111–112
    skeletal muscle mass maintenance in, 105, 110
  defined, 97
  liver disease severity effects on, 101
  metabolic and clinical responses related to, 95–131. See also Malnutrition, in cirrhosis
Satellite cells
  in sarcopenia in cirrhosis, 111–113
Scan test
  in semiquantification of OHE, 36
Shunting
  in OHE management, 84
  portosystemic
    cirrhosis with
      protein metabolism in, 110–111
Single-photon emission computed tomography (SPECT)
  in HE assessment, 65–67
Skeletal muscle mass
  in sarcopenia in cirrhosis, 111–112
Skeletal muscle protein metabolism
  molecular regulation of
    in sarcopenia in cirrhosis, 112–113
Sleep disturbances
  HRQoL effects on, 165–166
SONIC. See Spectrum of neurocognitive impairment in cirrhosis (SONIC)
SPECT. See Single-photon emission computed tomography (SPECT)
Spectrum of neurocognitive impairment in cirrhosis (SONIC), 204
Synergistic neurotoxins
  in HE pathogenesis, 10

T
T1-weighted MRI
  in HE assessment, 58–60
T2-weighted MRI
  DWI
    in HE assessment, 60–62
    fast FLAIR imaging
      in HE assessment, 60
TIPS. See Transjugular intrahepatic portosystemic shunt (TIPS)
Transjugular intrahepatic portosystemic shunt (TIPS)
  HE after, 133–146
    background of, 133
    characteristics of, 135–136
    described, 133–134
    incidence of, 135
    predictors of, 136–138
    prevention of, 138–139
    treatment of, 139–142
      chronic recurrent HE, 139–142
      episodic HE, 139
Transplantation
  liver
    HE after
      reversibility of, 147–158

V
Volumetric MRI
  in HE assessment, 62

W
West Haven Criteria (Conn Score)
  for semiquantification of OHE, 28–29